Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
What changed

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted

What changed: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted

Cancer page →

Every dated change on the records linked to Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Approval1Regulatory1Trial result5Milestone8This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordOligodendroglioma, IDH-mutant and 1p/19q-codeleted
Facts on this page last checked
When this page itself was last checked or edited.

August 2024 · 1

2024-08-06RegulatoryVorasidenib
Vorasidenib: approval (US)
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma

2024 · 2

2024ApprovalVorasidenib
Vorasidenib approved in US
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
2024MilestoneVorasidenib
FDA approves vorasidenib
A milestone in how this cancer is treated.

2023 · 2

2023Trial resultINDIGO
INDIGO reported
PFS 27.
2023MilestoneVorasidenib
INDIGO: vorasidenib in grade 2 astrocytoma and oligodendroglioma
A milestone in how this cancer is treated.

2021 · 1

2021Trial resultCODEL
CODEL reported
Temozolomide alone gave shorter progression-free survival than radiotherapy-containing treatment in 1p/19q-codeleted glioma; the redesigned comparison of radiotherapy with temozolomide against radiotherapy with PCV is ongoing.

2016 · 3

2016Trial resultEORTC 22033-26033
EORTC 22033-26033 reported
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
2016MilestoneProcarbazine
RTOG 9802: radiotherapy plus PCV for high-risk grade 2 glioma, including oligodendroglioma
A milestone in how this cancer is treated.
2016MilestoneOligodendroglioma, IDH-mutant and 1p/19q-codeleted
WHO 2016 defines oligodendroglioma by IDH mutation and 1p/19q codeletion
A milestone in how this cancer is treated.

2013 · 3

2013Trial resultEORTC 26951
EORTC 26951 reported
Median overall survival 42.
2013Trial resultRTOG 9402
RTOG 9402 reported
1p/19q co-deleted: median overall survival 14.
2013MilestoneRTOG 9402
Long-term results: radiotherapy plus PCV doubles survival in codeleted tumours
RTOG 9402 median 14.7 versus 7.3 years; EORTC 26951 median not reached versus 112 months (both JCO).

2006 · 1

2006MilestoneRTOG 9402
RTOG 9402 and EORTC 26951 report: PCV lengthens progression-free but not yet overall survival
A milestone in how this cancer is treated.

1998 · 1

1998MilestoneProcarbazine
Cairncross links 1p/19q loss to chemosensitivity
Journal of the National Cancer Institute report that codeleted anaplastic oligodendrogliomas respond to PCV and live longer.

1926 · 1

1926MilestoneOligodendroglioma, IDH-mutant and 1p/19q-codeleted
Bailey and Cushing describe oligodendroglioma as a distinct tumour
A milestone in how this cancer is treated.